臨床薬学講座 情報薬科学

• 講座概要
• 特徴的な臨床の取り組み
• 教授挨拶
• スタッフ
• 主な研究
• 主な業績

講座概要

薬物療法には、有効性や安全性に関する情報が不可欠です。医薬品情報は、創薬段階に加えて市販後にも継続的に更新されていきます。情報薬科学分野では、最新の情報を適切に収集・活用するための教育を担当しています。また、創薬における課題を解決するための研究と医療情報を解析して新たな課題を見つけ出す研究に取り組んでいます。

教授挨拶

医薬品として化学物質や生物由来成分をヒトに投与することには一定のリスクが伴います。このリスクをできるだけ抑え、薬物治療の効果を高めるためには、用法・用量、薬が体内でどのように動くか（体内動態）、薬の飲み合わせ（相互作用）、副作用などの医薬品情報が欠かせません。これらの情報は、10年以上に及ぶ創薬の過程（非臨床試験・臨床試験）で蓄積され、市販後も継続的に更新されます。

情報薬科学分野では、医薬品情報を適切に収集・活用するための教育に加え、近年進歩の著しい抗がん剤や抗感染症薬に関する教育を担当しています。また、創薬や薬物治療が抱える課題（新しい抗がん剤の開発、薬剤耐性、副作用、医療経済など）の解決を目指し、生命科学や情報科学、AIなどを活用した研究を行っています。さらに、医療情報を解析し、新たな課題や知見を見いだす研究にも取り組んでいます。

講座スタッフ

教授	西谷　直之	にしや　なおゆき
助教	氏家　悠貴	うじいえ　はるき
助教	佐京　智子	さきょう　ともこ
大学院生	半田　翔大	はんだ　しょうた
名誉教授・研究員	上原　至雅	うえはら　よしまさ

講座における主たる研究テーマ

1. 新しい抗がん剤の候補を見つける研究
2. がん細胞の弱点（新しい治療標的）を見つける研究
3. 抗がん剤の治療効果を予測する方法の開発
4. 抗がん剤耐性の仕組みの解明と克服
5. 抗がん剤の副作用を軽減する方法の開発
6. 医療情報を活用し新たな課題や知見を見つける研究

講座の主な業績

【令和７（2025）年度】

1. Ujiie H, Sakyo T, Oya K, Sugawara Y, Ota M, Yonezawa H, Nishiya N. Machine Learning–Driven Integration of Cancer Cell Phenotypes Predicts Cisplatin Sensitivity. Cancer Med. 2025 Nov;14(22):e71373.

【令和６（2024）年度】

1. Ujiie, H., Nishiya, N., Yamamoto, A., Takada, T., Onodera, M., Sasaki, A., Oikawa, T.: Dexamethasone reduces cisplatin-induced hair cell damage by inducing cisplatin resistance through metallothionein-2. Cancer. Chemother. Pharmacol. 2024 Oct;94(4):561-569.

【令和５（2023）年度】

1. Murakami Y, Imaizumi T, Hashizume K, Tezuka Y, Oku Y, Nishiya N, Atsushi Sanbe A, Kurosaka D. Inhibition of Connective Tissue Growth Factor Expression in Adult Retinal Pigment Epithelial-19 Cells by Blocking Yes-Associated Protein/Transcriptional Coactivator with PDZ-Binding Motif Activity. J. Ocul. Pharmacol. Ther. 2024 May 22;40(4):246-252.

【令和４（2022）年度】

1. Maeda, T., Nishi, T., Harada, M., Tanno, K., Nishiya, N., Asayama, K., Okuda, N., Sugiyama, D., Yatsuya, H., Okayama, A., Arima, H.: Influence of the COVID-19 pandemic on regular clinic visits and medication prescriptions among people with diabetes: Retrospective cohort analysis of health care claims. Medicine (Baltimore).  2022 Jul 22;101(29):e29458.
2. Katagiri, H., Yonezawa, H., Shitamura, S., Sugawara, A., Kawano, T., Maemondo, M., Nishiya, N. A Wnt/β-catenin signaling inhibitor, IMU1003, suppresses the emergence of osimertinib-resistant colonies from gefitinib-resistant non-small cell lung cancer cells. Biochem. Biophys. Res. Commun. 2023 Feb 19:645:24-29.

 【令和３（2021）年度】

1. Nishiya, N., Oku, Y., Ishikawa, C., Fukuda, T., Dan, S., Mashima, T., Ushijima, M., Furukawa, Y., Sasaki, Y., Otsu, K., Sakyo, T., Abe, M., Yonezawa, H., Ishibashi, F., Matsuura, M., Tomida, A., Seimiya, H., Yamori, T., Iwao, M., Uehara, Y. Lamellarin 14, a Derivative of Marine Alkaloids, Inhibits the T790M/C797S Mutant Epidermal Growth Factor Receptor. Cancer Sci. 2021 May;112(5):1963-1974.
2. Ujiie, H., Nihei, S., Nishiya, N., Goto, S., Asakura, Y., Miura, S., Hirai, D., Endo, M., Oyake, T., Ito, S., Chiba, T., Kudo, K.Switching from Intravenous to Oral Tacrolimus Reduces its Blood Concentration in Paediatric Cancer Patients. Anticancer Res. 2021 May;41(5):2591-2596.
3. Nishiya, N. and Yonezawa, H., Domestication of chemicals attacking metazoan embryogenesis: Identification of safe natural products modifying developmental signaling pathways in human. J. Antibiot (Tokyo). 2021 Oct;74(10):651-659. 
4. Harada, M., Nishi, T. Maeda, T., Tanno, K., Nishiya, N., Arima, H. How do Patients with Chronic Illnesses Respond to a Public Health Crisis? Evidence from diabetic patients in Japan during the COVID-19 pandemic. SSM Popul. Health. 2021 Dec;16:100961.
5. Ogishima, S., Tohoku Medical Megabank Project Study Group. dbTMM: an integrated database of large-scale cohort, genome and clinical data for the Tohoku Medical Megabank Project. Hum. Genome Var. 2021 Dec 10;8(1):44.
6. Yonezawa, H., Ikeda, A., Takahashi, R., Endo, H., Sugawara, Y., Goto, M., Kanno, M., Ogawa, S., Nakamura, K., Ujiie, H., Iwatsuki, M. Hirose, T., Sunazuka, T., Uehara, Y., Nishiya, N. Ivermectin represses Wnt/β-catenin signaling by binding to TELO2, a regulator of phosphatidylinositol 3-kinase-related kinases. iScience. 2022 Mar 7;25(3):103912.

【令和２（2020）年度以前】

1. Fukuda, T., Anzai, M., Nakahara, A., Yamashita, K., Matsukura, K., Ishibashi, F., Oku, Y., Nishiya, N., Uehara, Y., Iwao, M. Synthesis and evaluation of azalamellarin N and its A-ring-modified analogues as non-covalent inhibitors of the EGFR T790M/L858R mutant. Bioorg. Med. Chem. 2021 Mar 15:34:116039.
2. Yonezawa, H., Sugawara, A., Sakyo, T., Uehara, Y., Kawano, T., Nishiya, N., IMU1003, an atrarate derivative, inhibits Wnt/β-catenin signaling. Biochem. Biophys. Res. Commun. 2020 Nov 12;532(3):440-445.
3. Nishiya, N., Murai, M., Hosoda, A., Yonezawa, H., Omori, N., Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling. Pharmaceuticals, 2019 Nov 7;12(4):165.
4. Kuriyama, S., Tohoku Medical Megabank Project Study Group. Cohort Profile: Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study (TMM BirThree Cohort Study): Rationale, Progress and Perspective. Int. J. Epidemiol. 2020 Feb 1;49(1):18-19m
5. Yonezawa, H., Ogawa, M., Katayama, S., Shimizu, Y., Omori, N., Oku, Y., Sakyo, T., Uehara, Y., Nishiya, N. Clotrimazole inhibits the Wnt/β-catenin pathway by activating two eIF2α kinases: the heme-regulated translational inhibitor and the double-stranded RNA-induced protein kinase. Biochem. Biophys. Res. Commun. 2018 Nov 17;506(1):183-188.
6. Oku, Y., Nishiya, N., Sugiyama, S., Sato, H., Uehara, Y. Sensitisation of cancer cells to MLN8237, an Aurora-A inhibitor, by YAP/TAZ inactivation. Anticancer Res., 2018 Jun;38(6):3471-3476.
7. Oku, Y., Nishiya, N., Tazawa, T., Kobayashi, T., Umezawa, N., Sugawara, Y., Uehara, Y. Augmentation of the therapeutic efficacy of WEE1 kinase inhibitor AZD1775 by inhibiting the YAP–E2F1–DNA damage response pathway axis. FEBS Open Bio, 2018 May 22;8(6):1001-1012.
8. Fukuda T., Umeki T., Tokushima K., Xiang G., Yoshida Y., Ishibashi F., Oku Y., Nishiya N., Uehara Y., Iwao, M. Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant. Bioorg. Med. Chem. 2017 Dec 15;25(24):6563-6580.
9. Oku, Y., Nishiya, N., Tsuda, K., Shibazaki, M., Maesawa, C., Uehara, Y. Dynamic phenotypic transition of breast cancer cells in vitro revealed by self-floating cell culture. Anticancer Res. 2017 Apr;37(4):1793-1797.
10. Nishiya, N., Sakamoto, Y., Oku, Y., Nonaka, T., Uehara, Y. JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M. World J. Biol. Chem. 2015 Nov 26;6(4):409-418.
11. Oku, Y., Nishiya, N., Shito, T., Yamamoto, R., Yamamoto, Y., Oyama, C., Uehara, Y. Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers. FEBS Open Bio., 2015 Jun 22;5:542-549.
12. Nishiya, N. Chemical modifier screenings as methods for identifying pathway-targeting compounds and for predicting drug-drug interactions. Organic Chem. Curr. Res.2014 3:128. 
13. Nishiya, N., Oku, Y., Kumagai, Y., Sato, Y., Yamaguchi, E., Sasaki, A., Shoji, M., Ohnishi, Y., Okamoto, H., Uehara, Y. A Zebrafish Chemical Suppressor Screening Identifies Small Molecule Inhibitors of the Wnt/β-catenin Pathway. Chem. Biol., 2014 Apr 24;21(4):530-540.
14. Oku, Y., Tareyanagi, C., Takaya, S., Osaka, S., Ujiie, H., Yoshida, K., Nishiya, N., Uehara, Y. Multimodal Effects of Small Molecule ROCK and LIMK Inhibitors on Mitosis, and Their Implication as Anti-Leukemia Agents., PLoS One, 2014 Mar 18;9(3):e92402.
15. Tsuda, K., Nishiya, N., Umeyama, T., Uehara, Y. Identification of LY83583 as a specific inhibitor of Candida albicans MPS1 protein kinase. Biochem. Biophys. Res. Commun. 2011 Jun 10;409(3):418-423.
16. Jones, C.A., Nishiya, N., London, N.R., Zhu, W., Sorensen, L.K., Chan, A., Lim, C.J., Chen, H., Zhang, Q., Schultz, P.G., Hayallah, A.M., Thomas, K.R., Famulok, M., Zhang, K., Ginsberg, M.H., Li, D.Y. Slit2–Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nature Cell Biol. 2009 Nov;11(11):1325-1331.
17. Jones, C.A., London, N.R., Chen, H., Park, K.W., Sauvaget, D., Stockton, R.A., Wythe, J.D., Suh, W., Larrieu-Lahargue, F., Mukouyama, Y.S., Lindblom, P., Seth, P., Frias, A., Nishiya, N., Ginsberg, M.H., Gerhardt, H., Zhang, K., Li, D.Y. Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nature Med. 2008 Apr;14(4):448-453. 
18. Zhang, Q., Major, M.B., Takanashi, S., Camp, N.D., Nishiya, N., Peters, E.C., Ginsberg, M.H., Jian, X., Randazzo, P.A., Schultz, P.G., Moon, R.T., Ding, S. Small-molecule synergist of the Wnt/beta-catenin signaling pathway. Proc. Natl. Acad. Sci. USA. 2007 May 1;104(18):7444-7448.